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BACKGROUND. Prostate stem/progenitor cells function in glandular development and
maintenance. They may be targets for tumor initiation, so characterization of these cells may
have therapeutic implications. Cells from dissociated tissues that form spheres in vitro often
represent stem/progenitor cells. A subset of human prostate cells that form prostaspheres were
evaluated for self-renewal and tissue regeneration capability in the present study.
METHODS. Prostaspheres were generated from 59 prostatectomy specimens. Lineage marker
expression and TMPRSS-ERG status was determined via immunohistochemistry and
fluorescence in situ hybridization (FISH). Subpopulations of prostate epithelial cells were
isolated by cell sorting and interrogated for sphere-forming activity. Tissue regeneration
potential was assessed by combining sphere-forming cells with rat urogenital sinus
mesenchyme (rUGSM) subcutaneously in immunocompromised mice.
RESULTS. Prostate tissue specimens were heterogeneous, containing both benign and
malignant (Gleason 3–5) glands. TMPRSS-ERG fusion was found in approximately 70% of
cancers examined. Prostaspheres developed from single cells at a variable rate (0.5–4%) and
could be serially passaged. A basal phenotype (CD44þCD49fþCK5þp63þCK8ARPSA)
was observed among sphere-forming cells. Subpopulations of prostate cells expressing tumor-
associated calcium signal transducer 2 (Trop2), CD44, and CD49f preferentially formed spheres.
In vivo implantation of sphere-forming cells and rUGSM regenerated tubular structures
containing discreet basal and luminal layers. The TMPRSS-ERG fusion was absent in
prostaspheres derived from fusion-positive tumor tissue, suggesting a survival/growth
advantage of benign prostate epithelial cells.
CONCLUSION. Human prostate sphere-forming cells self-renew, have tissue regeneration
capability, and represent a subpopulation of basal cells. Prostate 70: 491–501, 2010.
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INTRODUCTION
Adult multipotential stem cells (SCs) are responsible
for the development, maintenance, and regeneration of
the range of specialized cell types comprising mam-
malian tissues [1,2]. Self-renewal is a fundamental
characteristic of SCs and refers to asymmetric divisions
that give rise to genetically identical daughter cells
in addition to more differentiated progenitors. Sub-
stantial evidence suggests that this process may be
deregulated in cancer, as transformed SCs or early
progenitors demonstrate uncontrolled self-renewal
that results in phenotypically diverse tumors [3–5].
Isolation of these cells may allow antigenic/molecular
profiling and the delineation of mechanisms that
regulate self-renewal and differentiation [5,6].
Several studies have attempted to identify human
prostate SCs [7–12]. Richardson et al. [10] found that
the a2b1
hi-integrin cells co-expressing CD133 had
increased proliferative activity, in vitro and limited
tissue regeneration capacity, in vivo. The CD133þ/
a2b1
hi cells represent a small fraction (<1%) of prostate
epithelial cells in benign and cancer tissues [8,10,12,13].
In a study of non-immortalized and immortalized
human prostate cell lines, prostate stem cells were
suggested to be CD133þ/ABCG2þ/a2b1hi/P63/
PSCA/AR/PSA based on the low frequency of
these cells in primary prostate epithelial (PrEC)
cultures in relation to neuroendocrine and transient
amplifying cells [12]. Additionally, sorted CD133þ
cells yielded cultures containing a mix of CD133þ and
CD133 prostate cells, representing the lineage cell
types [11,12].
In order to adequately analyze prostate SCs and
hierarchical order of prostate lineage cells derived
from human tissue, methods that enable the efficient
isolation and expansion of these rare cells is critical.
Culture conditions that support proliferation of pros-
tate cells that form spheres may represent a strategy for
SC isolation [8,14–16]. Spheres are multicellular globes
that develop from cells that survive anchorage-inde-
pendent conditions in vitro, such as growth in ultra-low
attachment (ULA) plates or 3D Matrigel cultures [17].
Spheres include SCs and early progenitors in studies of
breast, brain, and skin and are frequently used to study
the processes of self-renewal and differentiation in
these systems [14,18–20]. Lang et al. [21] observed
human sphere formation from dissociated prostate
tissue. Spheroid formation and branching morpho-
genesis with expression of luminal markers in response
to androgen and stromal growth factors was noted
when primary human prostate cells were grown in 3D
Matrigel cultures [21]. Other human studies have
suggested that prostasphere formation is a functional
validation of prostate SC activity in fractionated cell
lines or xenografts [9,22,23]. In order to further
characterize the relationship between stem/progenitor
cells and sphere-formation, self-renewal and tissue
regeneration properties of prostaspheres should be
addressed.
In the present study, a diverse collection of human
prostate surgical specimens was accrued and prosta-
spheres were generated reproducibly and robustly
from all prostate tissue types when cells were cultured
in low calcium, serum free, defined medium [12].
Clonally derived prostaspheres could be dissociated
and passaged for multiple generations and induced the
formation of ductal/acinar-like structures in vivo.
Trop2, alpha 6-integrin (CD49f), and CD44 mark cells
with enriched sphere-forming capability. The self-
renewing and differentiation features of prostaspheres
support preservation of SC activity in these cultures. As
previously suggested, low calcium, serum free culture
conditions that support human prostate stem/progen-
itor growth appears to select exclusively for normal
cells, since the TMPRSS-ERG fusion was never
observed in the prostaspheres derived from fusion
positive tissue specimens [11,12,24].
MATERIALSANDMETHODS
TissueAcquisition,Isolation, andCulture of
Prostate Epithelial Cells
Human prostate tissue was obtained from 59
patients (ages 41–76), undergoing prostate surgery
(radical prostatectomy or cystoprostatectomy). All
subjects were consented for tissue collection in accord-
ance with an approved protocol through the Office for
the Protection of Research Subjects at UCLA. For a list
of patient characteristics, see Supplemental Table I.
Adjacent tissue specimens were fixed in formalin and
paraffin-embedded to determine the presence of
benign or malignant glands. The remainder of the
tissue specimens were mechanically and enzymatically
digested as previously described [25]. Dissociated
prostate cell suspensions were sequentially filtered
through 100- and 40-mm filters, and then passed
through a 23-gauge needle. Cells were counted with a
hemocytometer and resuspended in PREGM (Clo-
netics) supplemented with FGF2 (Invitrogen), EGF
(Sigma), B27 (Invitrogen), and heparin (Sigma). The
cells were then cultured (as described below), or
subjected to cell separation using MACS beads col-
umns (Miltenyi Biotec LTD, Surrey, UK) or a cell sorter,
as described below.
Antigenic Cell Separation
Cells were mixed with MACS microbeads linked
to a cocktail of lineage antibodies (Lineage Depletion
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Kit, Miltenyi Biotec Ltd, Surrey, UK). After selection
through the magnetic column, lineage negative cells
were incubated with Trop-2 (R&D Systems), anti-CD44
(Abcam), anti-CD49f (Biolegend), or anti-CD133
(Miltenyi) antibodies, followed by incubation with
MACS goat anti-mouse IgG microbeads (Miltenyi)
and application to a MACS column. Alternatively,
Lin cells stained with fluorescent-linked primary
antibody were subjected to sorting. Sorted cells were
counted and plated in 3D Matrigel cultures.
InVitro Prostasphere Culture
Epithelial cells were counted and re-suspended in
50:50 matrigel:PREGM a concentration of 1 103–
6 104 cells/80 ml. This matrigel/cellular suspension
was plated at the edge of the well on 12-well plates and
allowed to set by incubation at 378C for 30 min. One
milliliter of defined media was then added to each
well and plates were replaced in 378C incubator.
For dissociation and passage of prostaspheres, 1-hr
incubation in 1 mg/ml Dispase (Invitrogen) was
performed. Spheres were collected, washed in RPMI,
and trypsinized (TripLE 100microliters/12-well plate).
Cells were washed, counted, and replated as described
above.
Lentiviral Infection of Prostate Epithelial Cells
Prostate epithelial cells were cultured in PREGM
for 48–72 hr. Viral supernatant containing lentivirus
(CCR-dsRed, a gift from the laboratory of Dr. Irvin
Chen at UCLA) and polybrene was added for 3 hr at
378C. Red fluorescence was detected 48–72 hr post-
infection. Monolayer cells were detached with TripLE
and plated in Matrigel for sphere formation.
Immunohistochemistryof
Tissue/Prostasphere Sections
Prostate tissue was paraffin embedded as previously
described [26]. For paraffin embedding of prosta-
spheres, matrigel cultures were subjected to Dispase
(1 mg/ml, Invitrogen) and whole prostaspheres were
collected and fixed in 10% buffered formalin at 48C for
12 hr. After fixation, prostaspheres were washed in PBS
and 50% ethanol, pelleted by centrifugation, and
resuspended in 10–20 ml of Histogel (Richard-Allen
Scientific). Four-micrometer thick sections of frozen or
paraffin embedded tissue were deparaffinized with
xylene and rehydrated through a descending series of
ethanol washes as described. Antigen retrieval and
standard immunoperoxidase procedures were used in
combination with primary antibodies. For Immuno-
fluorescence assays, permeablization of tissue was
performed using cold methanol:acetone, followed by
staining with antibodies.
Fluorescence-ActivatedCell Sorting andAnalysis
Prostate cells were suspended in PBS/10% FCS and
stained with antibody for 30 min at 48C. Fluorescence-
activated cell sorting and analysis are performed on a
BD Special Order FACSAria II system and Diva v6.1.1.
Live single cells are gated based on scatter properties
and analyzed for their surface marker expression. Cells
are sorted and collected at 408C using 100 mm nozzle
and 23 psi.
Subcutaneous Injections in
ImmunocompromisedMice
Male SCID mice age 8–24 weeks was subjected to
subcutaneous injections of prostaspheres 2 105 rat
urogenital sinus mesenchyme (rUGSM) suspended
in 100 ml 50:50 matrigel:PREGM. Subcutaneous im-
plantation of time-release testosterone pellets was
performed. Subcutaneous nodules at the site of
injection were removed and frozen/paraffin-
embedded sections were generated for immuno-
histochemical analysis. Rat UGSM was prepared as
previously described [27]. Fresh UGSM cells were
cultured in DMEMþ 10%FBS and passaged twice prior
to use in tissue regeneration assays.
FluorescenceActivated In SituHybridization
Paraffin-embedded human prostate tumor speci-
mens were subjected to FISH as previously described
[28]. Briefly, the break-apart assay is utilized with
probes that recognize the centromeric and telomeric
portions of the ERG gene. If there is a break in the gene,
distinct red and green signals are detected. If the gene
is intact, the red and green probes remain adjacent
and sometimes overlap, resulting in a yellow signal
(see Fig. 4).
RESULTS
ASmall FractionHuman Prostate CellsObtained
FromaDiverseCollection ofHumanProstateTumor
Specimens FormProstaspheres
To investigate whether sphere-forming cells may be
derived from all types of human prostate tissue,
specimens were obtained from 59 patients undergoing
radical prostatectomy or cystoprostatectomy. Patho-
logical examination of collected specimens confirmed
inclusion of either benign (normal and BPH) or a
mixture of benign and malignant glands with Gleason
grades ranging from 3 to 5 (Supplemental Table I).
Fresh tissues were mechanically and enzymatically
dissociated and single cells were seeded in ULA plates
or Matrigel at densities ranging from 102 to 105 cells/
well (Fig. 1, Supplemental Fig. 1). Prostaspheres
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formed from 21/24 specimens cultured in ULA plates
and 35/35 specimens cultured in Matrigel within 3 days
of plating, with continued growth over 2 weeks to
diameters of 100–400 mm (Fig. 1). There were only three
patient specimens that failed to for prostaspheres,
which may be attributed to variations in tissue proces-
sing as conditions were worked out. We observed that
Matrigel cultures facilitated enumeration of prosta-
spheres by preventing the aggregation of cells that
occurs in floating culture [14,29]. Sphere architecture
and marker expression was similar in both growth
conditions (Supplemental Fig. 1).
Although significant variability in the number of
prostaspheres that developed from individual patient
specimens was observed, consistent variation in the
number or appearance of prostaspheres according to
specific clinical or pathological parameters was not
apparent (Fig. 1A,B). Further prospective analysis
with dissection/isolation of tumor nodules may
allow more definitive conclusions on the relationship
of sphere-formation and Gleason grade. Tallies of
prostaspheres were obtained from a sample of
10 individual patients with varying pathologies
(benign to malignant) after replicate plating in
The Prostate
Fig. 1. Formation of prostaspheres fromdissociatedhumanprostate tissue.Prostate tissue obtained frompatients undergoing cancer sur-
gerywasmechanicallyandenzymaticallydigested.SinglecellswereandplatedinMatrigelseededatadensity2104/wellin6-wellculturedishes.
Adjacent tissue sampleswereparaffin-embeddedand stainedwithH&E for histological evaluation.Humanprostaspheresdevelopedrobustly
from all prostate specimens (A), includingbenignprostate tissue, low-grade (Gleason 3þ3) adenocarcinoma, andhigh-grade (Gleason 4þ 5)
adenocarcinoma.ProstaspheresderivedfromthesetissuesformedprostaspheresinMatrigel(A,lowerpanel).B:Prostasphereswereplatedin
triplicate in 6-well plates at a seeding density of1104 cells/well. After approximately14 days, prostaspheres were counted and the average
numberof spheres fromsevenindividualpatientswithpathologicaldiagnosis ofbenignprostate, low-grade, andhigh-grade adenocarcinoma is
depicted in the graph.Freshly dissociatedprostate cells were grown as amonolayer for 48hr followedby incubationwith lentivirus carrying
thegene for red fluorescentprotein (RFP).Redcellsweremixedwithuninfected (colorless) cells at a ratio of1:5 andplated inMatrigel culture
(1104 cells/well).Onlymonochromatic spheres were observed in (C) as seen in light and fluorescent views.Monochromatic spheres were
isolated andplatedby serial dilution intoULA96-wellplates so that1-sphere/wellwas obtained. Single sphereswere subjected to digestwith
TrypLE and single cellswere thenre-incubatedin PREGMmedia (D).Newmonochromatic sphereswerenoted to form from single cells after
2weeks of incubation (E).Frozen sections ofRFP/clear spheresdemonstrate that all cellswithin the sphere areredorclear andconfirmclono-
genicity (F).
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6-well culture dishes. The average number of pros-
taspheres obtained with similar seeding densities
per patient was plotted (Fig. 1B). The frequency of
sphere-forming cells derived from all 59 patients was
found to range from approximately 0.5–4% (data not
shown).
HumanProstaspheres are Clonally Derived
and Self-Renew
To confirm the clonal origin of prostaspheres, 105
freshly isolated prostate epithelial cells were grown as a
monolayer for 48 hr and then labeled with red
fluorescent protein via lentiviral-mediated gene trans-
fer of the dsRed gene. Approximately 90% of prostate
cells appeared to be expressing dsRed within 72 hr after
exposure to virus (data not shown). Infected (red)
prostate epithelial cells were detached and mixed with
wild-type (colorless) cells at a ratio of 1:5. The mixed
cell populations were plated in Matrigel in triplicate.
Approximately 7 days following plating, robust prosta-
sphere formation was observed and only monochro-
matic (all red or all colorless) prostaspheres were
identified, consistent with the concept of clonality
(Fig. 1C). Microscopic examination of frozen sections of
DSRED and clear prostaspheres demonstrated that all
cells within a single sphere were monochromatic
(Fig. 1C–E).
All of the prostasphere specimens cultured in
Matrigel could be passaged for multiple generations.
Repetitive passaging was specifically assessed in
four individual prostasphere cultures and more than
20 generations were obtained without any sign of
growth decline after dissociation and passage (data not
shown). DsRed-infected prostaspheres could also be
dissociated, mixed, and passaged repeatedly (>3
generations) with formation of new monochromatic
prostaspheres. Single red fluorescent prostaspheres
were isolated by serial dilution in 96-well plates,
followed by dissociation and incubation of single
cells in Matrigel. Secondary red prostaspheres were
noted to develop, supporting the self-renewal potential
of individual prostaspheres (Fig. 1C–F).
Prostate cells obtained from dissociated prosta-
spheres also remained viable after freeze/thaw, with
formation of new spheres in Matrigel that could be
serially passaged. Dissociated prostaspheres (passages
2–10) were cryopreserved for 1 month followed by
thaw and seeding in Matrigel. New prostaspheres
developed 7–10 days after plating that could be
passaged >3 generations (data not shown). Taken
together, these findings highlight the versatility of
prostaspheres, in that they can be genetically manip-
ulated, expanded continuously in vitro, and cryopre-
served.
Prostaspheres Express Predominately
BasalMarkers
The prostate epithelium is composed of basal cells,
including stem cells and transient amplifying cells,
terminally differentiated luminal cells, and neuro-
endocrine cells [30]. Prostate epithelial cells can be
differentiated based on expression of a variety of
markers [31]. The majority of basal cells express the
high molecular weight cytokeratins (CK5 and CK14),
p63, CD44, alpha integrin, and do not express signifi-
cant low molecular weight cytokeratins (CK8/18), AR
or PSA [12,25]. Luminal cells, in contrast, do not express
p63, but exhibit relatively high levels of AR, PSA, CK8/
18 [31]. Transient amplifying (intermediate) cells
express basal marker, CK5 and often co-express the
luminal marker, CK8 and prostate stem cell antigen
(PSCA) [25]. Neuroendocrine cells are express neuro-
peptides, including chromogranin A and synaptophy-
sin [31].
In order to determine the expression profile of
prostate epithelial cells within prostaspheres, immu-
nostaining was performed using antibodies against
several basal and luminal markers (Fig. 2A). The basal
markers CK5, alpha 6 integrin (CD49f), CD44, and p63
were strongly expressed by the majority of sphere-
forming cells. Greater than 95% of the sphere-forming
cells/20 objective high-powered field (hpf) appeared
to express CK5 and p63. Between 50% and 80% of cells/
hpf expressed CD44 and CD49f. Luminal markers,
including AR (androgen receptor) and PSA (prostate-
specific antigen) were not observed in prostaspheres
(data not shown). CK8 expression was noted in
approximately 1% of sphere-forming cells/hpf. Co-
expression with CK5 was seen in these cells (Fig. 2A).
We did not observe cells expressing the neuroendo-
crine markers, synaptophysin or Chromogranin A
(data not shown).
In addition to prostatic markers, the spheres were
assessed for cell proliferation and apoptosis via Ki-67
and TUNEL staining (Supplemental Fig. 2). Approx-
imately 2% of the sphere cells/hpf were observed to
have Ki-67 activity, with the outermost layer of the
sphere demonstrating the most activity. TUNEL stain-
ing was not clearly detected in prostaspheres (Supple-
mental Fig. 2).
Antigenic Prof|le ofHuman
Prostasphere-FormingCells
To determine the surface markers that identify
cells capable of prostasphere formation, we fractio-
nated subpopulations of prostate cells via microbeads
or automatic cell sorter separation (Fig. 2B–D).
Cell fractionation resulted in a variable decrease
(2–10-fold) in the overall number of prostaspheres
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formed following manipulation secondary to
decreased cell viability following these manipulations
(data not shown). However, comparison of fractio-
nated cell populations within individual specimens
allowed relative sphere-forming activity to be assessed.
In order to eliminate the possibility that cells of the
hematopoeitic lineage retained in the prostate tissue
contributed to the sphere-forming population, we
performed depletions with blood lineage antibodies.
FACS analysis with representative lineage antibodies
CD31 and CD45 confirmed removal of hematopoeitic/
endothelial cells (Supplemental 3B). Lin and Linþ
cells were plated in Matrigel cultures in several
replicates of 1 104cells/well to assess sphere-forming
activity. Prostaspheres formed exclusively in the Lin
cell fraction (Fig. 2B).
Previous investigations of human and murine
prostate SCs have suggested that CD44 may be an
important marker [10]. In order to investigate whether
CD44þ prostate epithelial cells were enriched for
sphere-forming capability, we used microbeads or
automatic cell sorting to isolate cells expressing this
antigen. FACS analysis confirmed enrichment of
CD44þ cells (Supplemental Fig. 3B). Plating of
CD44þ cells in Matrigel demonstrated enriched
sphere-forming capability (>2.5-fold) with 1/15
LinCD44þ cells forming spheres (Fig. 2B). Although
the presence of CD44 greatly enriched for sphere-
forming capability, some spheres were noted in the
LinCD44 fraction. This likely represents incomplete
separation of CD44þ and CD44 cells, but the possible
that a fraction of LinCD44 cells have sphere-
forming capability cannot be excluded.
We used a similar approach to examine whether
CD49f or the putative human prostate stem cell marker,
CD133, marked the sphere-forming population. FACS
analysis demonstrated CD49fþ (8–20%) and CD133þ
cells (2–7%) after lineage depletion (data not shown).
Fractionated prostate cells were evaluated by FACS
prior to seeding in Matrigel (Supplemental Fig. 3B). A
The Prostate
Fig. 2. Humanprostaspheres exhibit a predominatelybasal expressionprofile.Paraffin-embeddedhumanprostasphereswere stained for
prostateepithelialmarkers(A).H&Estaining,CD44(green),CK5(green),CK8(red),andp63(blue)areshownindividuallyaswellasco-staining.
B.Fractionationofdissociatedprostatecellsviaenrichment/depletionoflineage,CD44,CD49f,orCD133antigensdemonstratesphere-forming
capabilityof these cell populations. At least three differentpatient sampleswere testedper antigen.Lineage,CD44, andCD49f isolateswere
platedatarateof1104cellsperwell.CD133isolateswereplatedat1103 cells/well.C,D:Percentageofspheresformedfromprostateepithelial
cells sortedbasedonTrop2/CD44andTrop2/CD49fexpression.
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marked increase in sphere formation was observed
with LinCD49fþ cells compared to LinCD49f cells
(Fig. 2B). On the other hand, multiple attempts to
separate CD133þ and CD133 cells resulted in highly
variable results in sphere-forming capability. For most
of the patient samples, more spheres appeared to form
in the CD133 fraction, however, a smaller number of
spheres consistently formed within the CD133þ frac-
tion as well (Fig. 2B). Our difficulties in obtaining
consistent results with CD133 cell separation could be
due to the fact that the CD133þ cells are so rare, usually
composing 0.25–2% of unfractionated prostate cells.
This made isolation and plating in sphere cultures
difficult. We typically isolated <2 103 CD133þ cells
via this approach. Alternatively, CD133 as a solitary
marker may subdivide, but not distinguish the sphere-
forming population.
Our previous studies have demonstrated that
human prostate sphere-forming cells are similar to
murine prostate sphere-forming cells in regard to
antigenic profile. The epithelial marker, Trop2 in
combination with the high expression of the integrin,
CD49f (a marker of human basal cells), enables sphere-
forming cells to be isolated. Trop2 expression
appears confined to epithelial cells in the human
prostate and may be used in combination with other
markers to evaluate subpopulations of prostate epi-
thelial cells for sphere-forming capability. We per-
formed cell sorting based on Trop2/CD49f and Trop2/
CD44 expression and found that the double positive
fractions (Trop2þCD49fHI and Trop2þCD44þ) dem-
onstrate the highest sphere-forming capability in
multiple patients (Fig. 2C–D).
ProstaspheresDoNotContain theTMPRSS-ERG
Gene Rearrangement
Since the human prostaspheres were generated from
primary tumors that contain a heterogeneous mix of
benign and malignant glands, evaluation to distinguish
benign and cancerous spheres, was warranted. How-
ever, qualitative and quantitative differences were not
observed among prostaspheres derived from different
pathological specimens (Fig. 1). With the discovery of
prevalent gene rearrangements involving ETS family
members in prostate cancer, we predicted that cytoge-
netic tools may enable identification of cancerous
prostaspheres [28]. Gene fusions involving ERG,
ETV1, and ETV4 involve a variety of 50 partners that
direct aberrant expression of these transcription factors
and may initiate a cascade of events leading to
tumorigenesis [28]. The most common rearrangement
involves juxtaposition of the androgen-regulated
TMPRSS2 gene with ERG. TMPRSS-ERG gene fusions
have been detected in primary prostate tumor speci-
mens, metastases, and xenografts by fluorescence in
situ hybridization (FISH) [28]. Analysis of prostate
tumor surgical cohorts have found 36–78% of prostate
cancers possess the TMPRSS-ERG fusion [28]. The
presence of this fusion in individual prostaspheres may
suggest that cancer stem/early progenitor cells are
expanded in our cultures.
To test the feasibility of this approach, FISH analysis
was performed on select prostate tissue specimens and
coordinating prostaspheres (Fig. 3). The TMPRSS-ERG
fusion was found in approximately 7/10 (70%) cancer
cases tested (Fig. 3A). The fusion, however, was
consistently absent in prostasphere cultures derived
from TMPRSS-ERGþ tissues, even when the specimens
obtained contained >80% tumor (Fig. 3B–E). Analysis
of monolayer cultures concomitantly derived from
prostate tumor specimens also failed to demonstrate
the presence of the gene fusion, indicating that both
spheroid and adherent cultures select for fusion-
negative, genetically normal cells (data not shown).
Sphere-Mediated ProstateTissue Regeneration
To evaluate whether human prostaspheres can form
ductal/acini structures in vivo, whole prostaspheres
from eight patients were injected subcutaneously into
NOD-SCID/IL2rgNull mice with or without 2 105
rUGSM cells. The number of sphere forming cells
injected ranged from 5 104 to 1 106. All experiments
were performed in duplicate. In the mice injected with
whole prostaspheres combined with Matrigel, 10/16
grafts were obtained 6–12 weeks post-injection
(Fig. 4A). The grafts ranged in weight between
approximately 25 and 250 mg. Control mice injected
with rat UGSM without prostaspheres, were included
for comparison (Fig. 4A). Grafts were fixed in formalin
and embedded in paraffin to prepare tissue sections.
H&E staining revealed the prostaspheres induced
formation of acinar-like structures. No acini were
observed in the rUGSM only grafts. In the absence of
rUGSM, prostaspheres induced the development of
rudimentary appearing acini/epithelial cords with
multiple layers of epithelial cells and rare lumen
formation (Fig. 4A). On the other hand, when human
prostaspheres were combined with rat rUGSM and
Matrigel, acini contained well-defined lumens
with secretions (Fig. 4A). IHC analysis showed that
these acinar structures were reminiscent of normal
adult human adult prostate glands with CK8 and AR
positive luminal cells as well as CK5 and p63 positive
basal cells (Fig. 4B). Human prostate-specific markers,
prostate stem cell antigen (PSCA), prostate membrane
antigen (PSMA), and prostate specific antigen (PSA)
were also observed (Fig. 4B). Immunostaining for the
neuroendocrine markers synaptophysin and chromog-
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ranin A did not demonstrate neuroendocrine cells (data
not shown). Although prostaspheres regenerated
xenografts resembling normal human prostate, the
efficiency of glandular structure formation was rela-
tively low with 1–12 tubules ranging per 20/hpf. Our
results indicate that prostaspheres are capable of
glandular regeneration with basal and luminal com-
partments comparable to normal human prostate
tissue.
DISCUSSION
Sphere-formation in anchorage-independent con-
ditions is a characteristic of SCs initially described
in neural and mammary systems [16,18]. Studies of
murine prostate have demonstrated that a small
fraction of prostate epithelial cells expressing Sca-1
and alpha-6 integrin (CD49f), and Trop2 formed
spheres in 3D-Matrigel cultures that possessed
self-renewal and differentiation characteristics
[14,17,21,32]. Additionally, only the sphere-forming
fraction of murine prostate epithelial cells can induce
gland formation via in vivo tissue regeneration [17,33].
In human studies, in vitro prostate spheroid formation
with branching morphogenesis has been observed, but
self-renewal, tissue regeneration capability, and anti-
genic profiling to delineate the sphere-forming pop-
ulation was not addressed [32,34]. Here, we show that
0.5–4% of epithelial cells obtained from a wide variety
of dissociated human prostate specimens form prosta-
spheres that possess features of self-renewal, as
demonstrated by serial passage. Human prostaspheres
can also be dissociated and cryopreserved with the
retention of sphere-forming ability following thaw
(data not shown). These practical traits of human
prostaspheres enable viable repositories of prostate
stem/progenitor cells to be generated that could
facilitate high throughput studies of large collections
of patient specimens in the future.
In prior human prostate stem cell studies, epithelial
cells expressing a2b1
hi integrin, CD44, and CD133
have displayed stem-like qualities of increased pro-
liferative potential in vitro and regeneration of acinar-
like structures in vivo [7,10,13]. Consistent with
previous reports characterizing prostate SCs, the
putative SC markers, CD44 and a6 integrin (CD49f)
appeared to greatly enhance for the sphere-forming
population in this study, in addition to the epithelial
marker, Trop2. The CD133þ population was techni-
cally difficult to evaluate, given the small fraction of
these cells present in human prostate tissue specimens.
Furthermore, recent studies suggest that CD133 anti-
body binding may inhibit survival of these cells in vitro
[11]. It was observed that expression of CD133 did not
segregate basal epithelial cells based on sphere-form-
ing capability, since both CD133þ and CD133
fractions formed spheres. In contrast to CD44 and
CD49f, immunostaining and FACS of prostaspheres
failed to detect CD133, indicating that this marker is not
preserved in prostasphere cultures (data not shown).
The significance of CD133 expression should be
evaluated in future studies examining characteristics
of prostaspheres capable of tubule formation in vivo
(see below).
The marker profile of sphere-forming cells with
abundant expression of CK5 and p63 suggest that
normal basal cells were selected in our prostasphere
cultures. Basal markers are frequently lost in cancer
and malignant glands display a luminal phenotype that
The Prostate
Fig. 3. Patients undergoing radical prostatectomy for prostate
cancer were consented for tissue donation according to an
approved protocol through the Office for the Protection of
ResearchSubjects atUCLA.Patientinformationincluding age, pre-
operative prostate specific antigen (PSA), tumor location on final
pathology (R, Right, L, Left, A, Anterior, P, Posterior, Ap, Apex, B,
Base), and pathological stage (T2, tumor confined within the pro-
staticcapsule,T3,tumorextendsbeyondtheprostatecapsule)ispre-
sented in Panel A. Tissue specimens from these patients were
mechanically and enzymatically dissociated and cultured in 50:50
matrigel:PREGM (supplemented with EGF, FGF, and B27) to allow
prostasphere formation. Paraffin-embedded tumor specimens
and prostaspheres were subjected to FISH forTMPRSS-ERG gene
rearrangement.Humanprostate cancer FISHis showninPanels B
(40) and C (100) in a case that displays the ERG break-apart
genetic variation. In contrast, FISH of the prostaspheres shown in
PanelsD andE showanintactERGgenewithoverlapof theprobes.
None of the prostaspheres derived from patients with TMPRSS-
ERG fusion in their cancer specimens displayed a similar genetic
abnormality.
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includes abundant CK8/18 and AR expression, with
loss of CK5 and p63 [35]. Until the discovery of ETS
translocations, antigenic or genetic marker that clearly
delineated normal and cancerous prostate cells were
not available. With ETS family fusions now detectable
via FISH, genetic events associated with malignancy
can be evaluated in prostaspheres [28,36]. Consistent
with the benign basal marker profile of prostaspheres
and regenerated tubules, the TMPRSS-ERG fusion was
not identified in sphere-forming cells from fusionþ
tissue specimens. Although some of the collected tissue
specimens contained large tumor volumes (>80%
tumor glands), all of the prostaspheres demonstrated
a predominance of benign basal cells. Although it is
possible that prostate cancer stem/progenitor cells
do not contain gene rearrangements, a more
likely scenario is that the culture conditions that
support human prostate SC isolation and expansion
inhibit cancer cell outgrowth. This observation is
consistent with previous studies suggesting that cancer
cells do not proliferate in the defined medium typically
used to expand prostate epithelial cells [12,24]. Dis-
section of tumor nodules and outgrowth in more
permissive media conditions may enable selection of
prostate CSCs and will have to be addressed in future
studies [24].
The acinar structures observed in vivo also appeared
to resemble normal human prostate tissue, with
The Prostate
Fig. 4. Prostaspheres form acinar structures in immunocompromisedmice.Whole prostaspheres were isolated, mixedwithMatrigel and
injected subcutaneously intomice either with or without UGSM.Glandular-like structures were recovered 8^12 weeks after subcutaneous
implantation of whole prostaspheres (containing from 5104 to 1106 cells) suspended in Matrigel. A: H&E staining of graft containing
2105 rat UGSM only, graft containing regenerated prostate tissue induced by prostaspheres without UGSM, and graft of regenerated
prostate tissue formed by combining whole prostaspheres with 2105 rat UGSM.B: IHC analysis of the expression of CK5, p63, PSCA,
AR,CK8,andPSAinnormalhumanprostate tissue sections andaciniinducedbyprostaspheres (regeneratedgraft).
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preservation of discreet basal and luminal layers. In
vivo tissue regeneration occurred at low efficiency with
approximately 1 106 sphere forming cells yielding
scant tubules in regenerated grafts. One possibility for
the limited differentiation potential of prostaspheres is
that a significant proportion of develop from progen-
itor cells, not bona fide SCs, and are not capable of
tubule formation/maturation. To distinguish between
human prostate SCs and progenitors, it will be
necessary to further subdivide sphere-forming cells
and evaluate tissue regeneration capacity of fractio-
nated sphere-forming cells. It is possible that bona fide
SCs will have the exclusive ability to recapitulate
prostate glands in vivo, while progenitors will demon-
strate restricted differentiation.
CONCLUSIONS
Prostate sphere-forming cells include stem/progen-
itor cells that are capable of self-renewal and tissue
regeneration. Sphere forming cells exhibit a basal
profile that resembles benign prostate epithelial cells
and induce the formation of ductal/acinar structures
in vivo.
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